Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABANASDAQ:CKPTNASDAQ:FULCNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$1.87+7.5%$1.37$0.99▼$13.50$94.89M2.721.56 million shs1.13 million shsCKPTCheckpoint Therapeutics$4.23+1.0%$4.08$1.75▼$4.50$368.10M1.181.35 million shs12.19 million shsFULCFulcrum Therapeutics$6.90+8.7%$4.24$2.32▼$10.13$372.46M2.29970,384 shs997,784 shsPRTAProthena$4.60+0.4%$9.21$4.32▼$25.42$247.60M0.11661,731 shs6.24 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio+7.47%+4.18%+42.75%+3.31%-82.47%CKPTCheckpoint Therapeutics+0.95%+1.20%+2.92%+56.09%+136.31%FULCFulcrum Therapeutics+8.66%+10.40%+93.28%+104.75%-10.85%PRTAProthena+0.44%-32.55%-52.33%-69.60%-76.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCABACabaletta Bio3.1906 of 5 stars4.53.00.00.02.80.80.6CKPTCheckpoint Therapeutics2.3823 of 5 stars1.24.00.04.22.70.80.0FULCFulcrum Therapeutics0.5161 of 5 stars1.21.00.00.02.72.50.0PRTAProthena2.7232 of 5 stars4.21.00.00.02.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 3.00Buy$20.33987.34% UpsideCKPTCheckpoint Therapeutics 2.33Hold$4.332.44% UpsideFULCFulcrum Therapeutics 2.43Hold$5.83-15.46% DownsidePRTAProthena 2.33Hold$31.50584.78% UpsideCurrent Analyst Ratings BreakdownLatest CABA, PRTA, CKPT, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/16/2025CABACabaletta BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $13.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$5.51 per shareN/ACKPTCheckpoint Therapeutics$41K8,977.92N/AN/A($0.47) per share-9.00FULCFulcrum Therapeutics$80M4.66N/AN/A$3.80 per share1.82PRTAProthena$137.94M1.80N/AN/A$10.46 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$67.68M-$2.54N/AN/AN/AN/A-50.10%-45.49%8/14/2025 (Estimated)CKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%8/11/2025 (Estimated)FULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/14/2025 (Estimated)Latest CABA, PRTA, CKPT, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CABACabaletta Bio-$0.67-$0.71-$0.04-$0.71N/AN/A5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/31/2025Q4 2024CABACabaletta Bio-$0.65-$0.65N/A-$0.65N/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/ACKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A8.118.11CKPTCheckpoint TherapeuticsN/A0.290.29FULCFulcrum TherapeuticsN/A18.4418.44PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/ACKPTCheckpoint Therapeutics22.00%FULCFulcrum Therapeutics89.83%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%CKPTCheckpoint Therapeutics2.10%FULCFulcrum Therapeutics7.00%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio5050.74 million44.05 millionOptionableCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableCABA, PRTA, CKPT, and FULC HeadlinesRecent News About These CompaniesChardan Capital Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 29 at 1:15 AM | americanbankingnews.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 29 at 12:57 AM | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28 at 2:24 PM | insidermonkey.comPiper Sandler Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 28 at 11:29 AM | marketbeat.comProthena Target of Unusually High Options Trading (NASDAQ:PRTA)May 28 at 10:38 AM | marketbeat.comJMP Securities Cuts Prothena (NASDAQ:PRTA) Price Target to $29.00May 28 at 9:30 AM | marketbeat.comProthena (NASDAQ:PRTA) Downgraded by Cantor Fitzgerald to NeutralMay 28 at 9:13 AM | marketbeat.comProthena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to HoldMay 28 at 9:13 AM | marketbeat.comProthena (NASDAQ:PRTA) Cut to Market Perform at OppenheimerMay 28 at 9:13 AM | marketbeat.comChardan Capital Lowers Prothena (NASDAQ:PRTA) Price Target to $18.00May 28 at 8:15 AM | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 28 at 8:15 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Prothena (PRTA) and Bristol-Myers Squibb (BMY)May 28 at 4:44 AM | theglobeandmail.comJMP Securities Lowers Prothena (NASDAQ:PRTA) Price Target to $29.00May 28 at 3:04 AM | americanbankingnews.comProthena (NASDAQ:PRTA) Downgraded to Neutral Rating by Cantor FitzgeraldMay 28 at 2:28 AM | americanbankingnews.comProthena (NASDAQ:PRTA) Downgraded to Hold Rating by Jefferies Financial GroupMay 28 at 2:28 AM | americanbankingnews.comHC Wainwright Lowers Prothena (NASDAQ:PRTA) Price Target to $14.00May 28 at 1:53 AM | americanbankingnews.comPeninsula biotech Prothena falters — again — and layoffs are on the wayMay 27 at 6:43 PM | bizjournals.comProthena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In PlaceMay 27 at 6:43 PM | seekingalpha.comProthena hits 52-week low amid downgrades after late-stage trial setbackMay 27 at 6:43 PM | msn.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 27 at 1:28 PM | insidermonkey.comProthena's Late-Stage Study for AL Amyloidosis Fails, Stock DownMay 27 at 11:21 AM | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCABA, PRTA, CKPT, and FULC Company DescriptionsCabaletta Bio NASDAQ:CABA$1.87 +0.13 (+7.47%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.87 +0.00 (+0.05%) As of 05/28/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Checkpoint Therapeutics NASDAQ:CKPT$4.23 +0.04 (+0.95%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.23 0.00 (0.00%) As of 05/28/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Fulcrum Therapeutics NASDAQ:FULC$6.90 +0.55 (+8.66%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$7.42 +0.52 (+7.54%) As of 05/28/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Prothena NASDAQ:PRTA$4.60 +0.02 (+0.44%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.58 -0.02 (-0.43%) As of 05/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
